
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is expected to see an increase in operating expenses in 2026 as they initiate their Phase 2b/3 trial in CSU. However, with $13.4M in cash and equivalents on hand from 2025, the company should have sufficient funds to support operations until late 2026/early 2027. Despite posting negative EPS of ($2.93) in 2025, which is expected to decrease in 2026, the company's unique platform for allogeneic iNKT cell therapy for cancer and other immune-mediated diseases, offers strong potential for future growth.
Bears say
MiNK Therapeutics is facing potential risks as they collaborate with C-Further, potentially signaling inadequate competitiveness, while their IPO undisputedly showcases a weak cash flow position. This combination, coupled with uncertain efficacy and the company's limited pipeline assets and indications, make them an unattractive investment with a negative long-term outlook.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares